AbbVie Reports Third-Quarter 2026 Financial Results
AbbVie (ABBV) reported Q3 2026 net revenues of $17.404B, up 10.3%. GAAP EPS was $2.37, adjusted EPS $3.82. Skyrizi and Rinvoq revenues grew 22.7% and 23.9% respectively. Humira revenues declined 31.2%. AbbVie raised 2026 adjusted EPS guidance to $13.95-$13.99 and announced a 5.2% dividend increase for 2027.
How this was made
The 30-second read
Why it matters
The earnings beat and raised guidance are likely to drive short-term buying pressure, while the acquisition of Apogee Therapeutics adds long-term growth potential.
Market read
AbbVie's earnings and guidance raise are material for investors and can influence the broader healthcare sector.
What to watch
Acquisition integration risk and higher R&D spend could pressure margins.
Background
AbbVie released its third-quarter 2026 financial results, including revenue growth, EPS figures, and guidance updates.
Ticker impact
AbbVie reported Q3 2026 earnings with revenue up 10.3% and raised full-year adjusted EPS guidance.
likely upside as market prices in higher guidance and dividend increase
Higher guidance and a 5.2% dividend hike suggest improved profitability, supporting price appreciation.
Market effects
Positive earnings may lift the healthcare and pharma sector.
Boosts US market sentiment, especially large-cap biotech stocks.
Sets a positive tone for global pharma equities.
Counterpoint
If guidance raise is already priced in, the stock could face short-cover pullback.
Key entities
- companyAbbVie
US-listed biopharma company reporting Q3 results.
- companyApogee Therapeutics
Acquired biotech expanding AbbVie's immunology pipeline.
